Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data.

Dysken MW, Guarino PD, Vertrees JE, Asthana S, Sano M, Llorente M, Pallaki M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Carney S, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Vatassery G.

Alzheimers Dement. 2014 Jan;10(1):36-44. doi: 10.1016/j.jalz.2013.01.014. Epub 2013 Apr 11.

2.

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.

Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD.

JAMA. 2014 Jan 1;311(1):33-44. doi: 10.1001/jama.2013.282834. Erratum in: JAMA. 2014 Mar 19;311(11):1161.

3.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group.

Curr Alzheimer Res. 2008 Feb;5(1):83-9.

PMID:
18288936
4.

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.

Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, Jia XD, Pejović V, Miller ML, Perhach JL, Graham SM.

CNS Drugs. 2013 Jun;27(6):469-78. doi: 10.1007/s40263-013-0077-7.

5.

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group.

JAMA. 2004 Jan 21;291(3):317-24.

PMID:
14734594
6.

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S.

Am J Geriatr Psychiatry. 2006 Aug;14(8):704-15.

PMID:
16861375
7.

Memantine for dementia.

Areosa SA, Sherriff F.

Cochrane Database Syst Rev. 2003;(3):CD003154. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD003154.

PMID:
12917950
8.

Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

Wilkinson D, Andersen HF.

Dement Geriatr Cogn Disord. 2007;24(2):138-45. Epub 2007 Jul 4.

PMID:
17622761
9.
10.

Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.

Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P; Alzheimer’s Disease Cooperative Study.

Arch Neurol. 2012 Jul;69(7):836-41.

11.

Memantine for dementia.

Areosa Sastre A, McShane R, Sherriff F.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003154. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD003154.

PMID:
15495043
12.

Memantine in Alzheimer's disease: experience in an Alzheimer's disease assessment unit.

Sinforiani E, Pasotti C, Chiapella L, Malinverni P, Zucchella C.

Aging Clin Exp Res. 2012 Apr;24(2):193-6.

PMID:
22842837
13.

Vitamin E for Alzheimer's dementia and mild cognitive impairment.

Farina N, Isaac MG, Clark AR, Rusted J, Tabet N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD002854. doi: 10.1002/14651858.CD002854.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Jan 27;1:CD002854.

PMID:
23152215
14.
15.

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ.

N Engl J Med. 1997 Apr 24;336(17):1216-22.

16.

Memantine for dementia.

Areosa SA, Sherriff F.

Cochrane Database Syst Rev. 2003;(1):CD003154. Review. Update in: Cochrane Database Syst Rev. 2003;(3):CD003154.

PMID:
12535459
17.

Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial.

Annweiler C, Fantino B, Parot-Schinkel E, Thiery S, Gautier J, Beauchet O.

Trials. 2011 Oct 20;12:230. doi: 10.1186/1745-6215-12-230.

18.

The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.

Zhang N, Wei C, Du H, Shi FD, Cheng Y.

Dement Geriatr Cogn Disord. 2015;40(1-2):85-93. doi: 10.1159/000430808. Epub 2015 Jun 5.

PMID:
26066622
20.

Vitamin E for Alzheimer's disease and mild cognitive impairment.

Isaac MG, Quinn R, Tabet N.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD002854. doi: 10.1002/14651858.CD002854.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;11:CD002854.

PMID:
18646084

Supplemental Content

Support Center